NCT03901781View on ClinicalTrials.gov

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 23, 2019

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Ocular Hypertension
Interventions
COMBINATION_PRODUCT

ST266 via Intranasal Delivery

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
lead

Noveome Biotherapeutics, formerly Stemnion

INDUSTRY

NCT03901781 - Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects | Biotech Hunter | Biotech Hunter